Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 2 Drug-Related Side Effects and Adverse Reactions 2 Cardiovascular Diseases 2 Cardiotoxicity 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Leukemia, Myeloid 1 Leukemia, Monocytic, Acute 1 Leukemia, Lymphoid 1 Leukemia 1 Kidney Neoplasms 1 Hodgkin Disease 1

Interventions

pembrolizumab 157 Gemcitabine 140 Capecitabine 123 Paclitaxel 121 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 99 Docetaxel 98 Leucovorin 97 Cisplatin 90 Radiosurgery 88 Irinotecan 88 Carboplatin 86 Cyclophosphamide 72 Cetuximab 72 Magnetic Resonance Spectroscopy 68 Specimen Handling 60 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Ipilimumab 53 Drug Therapy 51 Everolimus 48 Pemetrexed 46 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 40 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × Social Determinants of Health × Clear all

NCT06081517 2025-06-13

EDPO

Indiana University

10,600 enrolled

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡